Lidocaine HCl Injection, USP 1 % 50 mg/5 mL (10 mg/mL), 5mL vial, Rx only, Mrd. in India for: Au...
FDA Drug Recall #D-1248-2019 — Class I — March 28, 2019
Recall Summary
| Recall Number | D-1248-2019 |
| Classification | Class I — Serious risk |
| Date Initiated | March 28, 2019 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Aurobindo Pharma USA Inc. |
| Location | East Windsor, NJ |
| Product Type | Drugs |
| Quantity | 88600 vials |
Product Description
Lidocaine HCl Injection, USP 1 % 50 mg/5 mL (10 mg/mL), 5mL vial, Rx only, Mrd. in India for: AuroMedics Pharna LLC. E Windsor, NJ 08520 NDC 55150-162-05
Reason for Recall
Presence of Particulate Matter: One vial was found to contain a hair.
Distribution Pattern
Product is being held at a distributor site in Mexico, Asheboro, NC, Charlotte, NC and Santa Teresa, NM and not further distributed in the U.S. Market.
Lot / Code Information
Lot #: CLC180117, Exp. June 2021
Other Recalls from Aurobindo Pharma USA Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0492-2024 | Class II | Clorazepate Dipotassium Tablets, USP, 7.5 mg, a... | Apr 24, 2024 |
| D-0491-2024 | Class II | Clorazepate Dipotassium Tablets, USP, 3.75 mg, ... | Apr 24, 2024 |
| D-1171-2023 | Class II | Rasagiline Tablets 0.5mg, 30-count bottle, Rx o... | Aug 2, 2023 |
| D-1087-2023 | Class II | Rufinamide Tablets, USP 200 mg, packaged in 120... | Jul 21, 2023 |
| D-1088-2023 | Class II | Rufinamide Tablets, USP 400 mg, packaged in 120... | Jul 21, 2023 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.